DFTX
insider transactionsDefinium Therapeutics, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 90d
-43.2K
0 buy · 43.2K sell
Net value · 90d
-$797.0K
$0 in · $797.0K out
Sentiment · 90d
Net selling
0% buying · 100% selling
Open-market trades · 90d
3
0 buy · 43.2K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Director
$0
19.2K sh
Own New
-
Grant·A
Director
$0
4.7K sh
Own +31%
-
Grant·A
Director
$0
19.2K sh
Own New
-
Grant·A
Director
$0
4.7K sh
Own +28%
-
Grant·A
Director
$0
19.2K sh
Own New
-
Grant·A
Director
$0
4.7K sh
Own +31%
-
Grant·A
Director
$0
19.2K sh
Own New
-
Grant·A
Director
$0
4.7K sh
Own +24%
-
Grant·A
Director
$0
19.2K sh
Own New
-
Grant·A
Director
$0
4.7K sh
Own +24%
-
Grant·A
Director
$0
12.0K sh
Own New
-
Grant·A
Director
$0
4.0K sh
Own +14%
-
Sell·S
Chief Medical Officer · 10b5-1
$148.1K
8.0K sh · $18.47
Own -2%
-
Sell·S
Chief Legal Officer · 10b5-1
$197.7K
10.7K sh · $18.47
Own -4%
-
Sell·S
Robert Barrow KEY
Chief Executive Officer · 10b5-1
$451.2K
24.4K sh · $18.47
Own -3%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 11, 2026 | David W Gryska | Grant A | 19.2K | $0 |
| Jun 11, 2026 | David W Gryska | Grant A | 4.7K | $0 |
| Jun 11, 2026 | Carol A Vallone | Grant A | 19.2K | $0 |
| Jun 11, 2026 | Carol A Vallone | Grant A | 4.7K | $0 |
| Jun 11, 2026 | Andreas Krebs | Grant A | 19.2K | $0 |
| Jun 11, 2026 | Andreas Krebs | Grant A | 4.7K | $0 |
| Jun 11, 2026 | Roger Crystal | Grant A | 19.2K | $0 |
| Jun 11, 2026 | Roger Crystal | Grant A | 4.7K | $0 |
| Jun 11, 2026 | Suzanne Louise Bruhn | Grant A | 19.2K | $0 |
| Jun 11, 2026 | Suzanne Louise Bruhn | Grant A | 4.7K | $0 |
| May 19, 2026 | Suzanne Louise Bruhn | Grant A | 12.0K | $0 |
| May 19, 2026 | Suzanne Louise Bruhn | Grant A | 4.0K | $0 |
| Mar 25, 2026 | Daniel Karlin 10b5-1 | Sell S | 8.0K | $148.1K |
| Mar 25, 2026 | Mark Sullivan 10b5-1 | Sell S | 10.7K | $197.7K |
| Mar 25, 2026 | Robert Barrow KEY 10b5-1 | Sell S | 24.4K | $451.2K |
About DFTX insider trading
This page tracks insider transactions for Definium Therapeutics, Inc. (DFTX) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.